Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
Federal funding opportunity RFA-TR-25-016 from National Institutes of Health.
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- September 29, 2025
- Closes
- See announcement
- Program funding
- $1,600,000
- Expected awards
- 2
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.350
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.350 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $588.2M
- FY2025 obligated
- $599.3M
- FY2026 (to date) obligated
- $281.4M
- Awards in window
- 886
Top recipients: Vanderbilt University Medical Center, Regents of the University of Michigan, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, The Johns Hopkins University
Source: USAspending.gov · refreshed July 2026
Synopsis
NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases.
The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Who can apply
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- State governments
- City or township governments
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- County governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal governments (Federally recognized)
- Special district governments
- Public housing authorities/Indian housing authorities
- Small businesses
- Independent school districts
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-Eligible ApplicantsNon-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts